Advancing advanced therapies
A Belgian recipe for an innovative ecosystem
As Advanced Therapies are entering a next stage of commercialization, the challenges become more apparent, while the investment opportunity remains ‘risky but high’. Deloitte has been on the ground in bringing advanced therapies from the lab to the patient. Developed in collaboration with BioWin and MEDVIA, this paper ids a reflection on the field, the challenges and opportunities for the Belgian ecosystem to address these challenges.
Our three key takeaways:
- Rapid pace of scientific innovation drives broader utilization for advanced therapies (beyond rare diseases) and higher feasibility to adopt in clinical practice (reducing COGS to improve affordability).
- Yet, an advanced therapy ecosystem with the right level of funding and maturity across the value chain (e.g., manufacturing, logistics, talent, etc.) is a must for patient access and outcomes (i.e., enabling quality and performance of advanced therapies at commercial scale).
- Belgium has all the right ingredients to tackle the challenges in the supply chain and establish itself as the biomanufacturing gateway to Europe, building on specialized logistics, multi-disciplinary academic centers, access to biomanufacturing infrastructure, novel funding schemes and innovative healthcare system in the heart of Europe
